26.12.2012 Views

Toxicology of Industrial Compounds

Toxicology of Industrial Compounds

Toxicology of Industrial Compounds

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

378 INDEX<br />

mRNA analysis 211<br />

Mutagenic potency 190–6<br />

Mutagenicity, surfactants 349–2<br />

N 7 -deoxyguanosine (N 7 -dG) 186<br />

NADPH-cytochrome P450 reductase<br />

15<br />

Naphthalene diisocyanate (NDI) 151<br />

β-naphth<strong>of</strong>lavone 266, 267<br />

2-naphthylamine 40–3, 301<br />

Neuropathy target esterase (NTE) 238<br />

Neurotoxicity, biomarkers <strong>of</strong> 238–4<br />

Neurotoxicity assessment 285<br />

Neurotoxicity testing 237–56<br />

Neurotypic proteins 238–3<br />

Nitroarenes 74, 77<br />

NK activity 199<br />

NK test 200<br />

NOAEL 168, 174, 367<br />

NOEL 43, 366, 367<br />

Nucleophilic centres 73<br />

Occupational asthma 148–9<br />

chemical agents causing 148–5<br />

incidence 148, 151<br />

initial diagnosis 149<br />

Occupational toxicology, monitoring in<br />

19–1<br />

OECD guidelines 421 282–7<br />

OECD guidelines 422 282–91<br />

OECD single generation study 283<br />

17β-oestradiol 212<br />

Organic solvents<br />

absorption <strong>of</strong> 3–7<br />

biological monitoring <strong>of</strong> 2–3<br />

dermal uptake <strong>of</strong> 5–7<br />

pulmonary uptake <strong>of</strong> 3–5<br />

Organophosphate-induced delayed<br />

neuropathy (OPIDN) 238<br />

Organophosphate pesticides 237–2<br />

Parkinson’s disease 241, 245<br />

PBPK/PBTK models<br />

1,3-butadiene 16<br />

2-butoxyethanol 166–4, 172–80<br />

development <strong>of</strong> 31–3<br />

in risk assessment 170–80<br />

PCA-DNA adducts 187<br />

PCNB 267<br />

Pentafluorophenyl isothiocyanate<br />

(PFPITC) 76<br />

Pentafluorophenyl thiohydantoine<br />

(PFPTH) 77<br />

Perchlorate-discharge test 260<br />

Peroxisome proliferation 223–40<br />

carcinogenicity 224–30<br />

in rodent liver 223–8<br />

mechanisms <strong>of</strong> 226–1<br />

risk assessment 229–5<br />

rodent 223–9<br />

species differences in response 227–3<br />

Pesticides 203, 202<br />

human exposure to 208<br />

immunotoxicity <strong>of</strong> 203<br />

organophosphate 237–2<br />

Pharmaceuticals 202<br />

Phencyclidine 48<br />

Phenobarbital 267, 273<br />

Phenobarbitone 322<br />

Phenolic antioxidants 316–25<br />

blood kinetics 317–1<br />

blood metabolites 317–1<br />

effects on serum thyrotropin and<br />

thyroid hormones 318–4<br />

liver enzyme induction 318–2<br />

model compound 317<br />

risk assessment 321–5<br />

Phthalate esters 223, 224<br />

Phthalic anhydride 152<br />

Physiologically-based pharmaco<br />

(toxico-) kinetic models. See PBPK/<br />

PBTK models<br />

Phytopharmaceuticals 208<br />

Pigments. See Colorants (dyes and<br />

pigments)<br />

Plaque assay (PFCA) 199, 200<br />

Plasticisers 223, 229–4<br />

Polychlorinated biphenyls (PCBs) 247–<br />

2, 267<br />

Polycyclic aromatic hydrocarbons<br />

(PAHs) 74–7, 78, 158, 186<br />

biomonitoring exposure 158–6<br />

Polyisocyanates 151–6<br />

Postlabelling 78–79, 81<br />

Post-natal manifestations 284

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!